Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02732171 · ClinicalTrials.gov registry record · NA

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

A NA study of Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

Recruiting
Registry status
NA
Development phase
600
Enrollment target
1
Study location

NCT02732171: Recruiting NA study of Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

NCT02732171 is a NA study of Breast Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 600 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02732171, a NA study of Breast Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.

RECRUITING
Registry status
NA
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

This is a single center, prospective cross-sectional study of women who have completed therapy for primary breast cancer within 5 years of diagnosis and are at increased risk for relapse. Patients will undergo screening bone marrow aspirate to test for presence of disseminated tumor cells (DTCs) Patients who harbor DTCs will be offered the opportunity for enrollment into a clinical trial of therapy targeting DTCs to prevent recurrence (separate protocols).

Primary Outcome

Bone marrow sample is evaluated for DTCs by a standard immunohistochemistry assay (DTC-IHC)

Conditions Studied

Interventions

  • OTHER Research Blood Collection

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2016-04
Est. Completion 2030-04
Phase NA

What NCT02732171 shows while recruiting

NCT02732171 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Research Blood Collection is the first listed.

NCT02732171 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02732171 about?

NCT02732171 is a clinical study titled "PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer". This is a single center, prospective cross-sectional study of women who have completed therapy for primary breast cancer within 5 years of diagnosis and are at increased risk for relapse. Patients will undergo screening bone marrow aspirate to test for presence of disseminated tumor cells (DTCs) Pa...

What is the current status of trial NCT02732171?

This trial is currently recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2016-04. Estimated completion is 2030-04.

What conditions does trial NCT02732171 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02732171?

The interventions under investigation include: Research Blood Collection (OTHER).

Who is sponsoring clinical trial NCT02732171?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02732171 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02732171's enrollment target sits among peer trials

600 177th of 1224 higher than 1,044 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02732171, the US trial registry maintained by the National Library of Medicine. NCT02732171 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.